Literature DB >> 8834196

Celiprolol double-peak occurrence and gastric motility: nonlinear mixed effects modeling of bioavailability data obtained in dogs.

E Lipka1, I D Lee, P Langguth, H Spahn-Langguth, E Mutschler, G L Amidon.   

Abstract

Investigation of the underlying mechanism leading to inter- and intrasubject variations in the plasma concentration-time profiles of drugs (1) can considerably benefit rational drug therapy. The significant effect of gastric emptying on the rate and extent of celiprolol absorption and its role with respect to double-peak formation was demonstrated in the present study. In four dogs racemic celiprolol was dosed perorally in a crossover design during four different phases of the fasted-state gastric cycle and gastric motility was recorded simultaneously using a manometric measurement system. Intravenous doses were also given to obtain disposition and bioavailability parameters. The blood samples were assayed by a stereoselective HPLC method (2). The time to onset of the active phase of the gastric cycle showed an excellent correlation with the time to celiprolol peak concentration. Furthermore, bioavailability was increased when celiprolol was administered during the active phase. Double peaks were observed when the first active phase was relatively short, suggesting that a portion of the drug remained in the stomach until the next active phase. Population pharmacokinetic modeling of the data with a two-compartment open model with two lag times incorporating the motility data confirmed the effect of time to gastric emptying on the variability of the oral pharmacokinetics of celiprolol. The fasted-state motility phases determine the rate and extent of celiprolol absorption and influence the occurrence of double peaks. Peak plasma levels of celiprolol exhibit less variability if lag times, and therefore gastric emptying times, are taken into consideration.

Entities:  

Keywords:  Non-programmatic

Mesh:

Substances:

Year:  1995        PMID: 8834196     DOI: 10.1007/bf02354285

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  26 in total

1.  Pharmacokinetics of pafenolol after i.v. and oral administration of three separate doses of different strength to man.

Authors:  C G Regardh; A Heggelund; K Kylberg-Hanssen; P Lundborg
Journal:  Biopharm Drug Dispos       Date:  1990-10       Impact factor: 1.627

2.  Intestinal absorption of a beta-adrenergic blocking agent nadolol. I. Comparison of absorption behavior of nadolol with those of other beta-blocking agents in rats.

Authors:  T Yamaguchi; C Ikeda; Y Sekine
Journal:  Chem Pharm Bull (Tokyo)       Date:  1986-08       Impact factor: 1.645

3.  Kinetics of acetaminophen absorption and gastric emptying in man.

Authors:  J A Clements; R C Heading; W S Nimmo; L F Prescott
Journal:  Clin Pharmacol Ther       Date:  1978-10       Impact factor: 6.875

4.  The pharmacokinetics of penicillamine in a female mongrel dog.

Authors:  R F Bergstrom; R D Kay; J G Wagner
Journal:  J Pharmacokinet Biopharm       Date:  1981-10

5.  The contribution of intestinal secretion to the dose-dependent absorption of celiprolol.

Authors:  S M Kuo; B R Whitby; P Artursson; J A Ziemniak
Journal:  Pharm Res       Date:  1994-05       Impact factor: 4.200

6.  Comparative enantioselective pharmacokinetic studies of celiprolol in healthy volunteers and patients with impaired renal function.

Authors:  C Hartmann; M Frölich; D Krauss; H Spahn-Langguth; H Knauf; E Mutschler
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

7.  Absorption of flurbiprofen in the fed and fasted states.

Authors:  J B Dressman; R R Berardi; G H Elta; T M Gray; P A Montgomery; H S Lau; K L Pelekoudas; G J Szpunar; J G Wagner
Journal:  Pharm Res       Date:  1992-07       Impact factor: 4.200

8.  Correlation of ibuprofen bioavailability with gastrointestinal transit by scintigraphic monitoring of 171Er-labeled sustained-release tablets.

Authors:  A F Parr; R M Beihn; R M Franz; G J Szpunar; M Jay
Journal:  Pharm Res       Date:  1987-12       Impact factor: 4.200

9.  Implications of intraindividual variability in bioavailability studies of furosemide.

Authors:  A Grahnén; M Hammarlund; T Lundqvist
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

10.  Pharmacokinetics of pafenolol in the rat: a suitable model for studying absorption mechanisms of a drug exhibiting unusual absorption properties in man.

Authors:  H Lenneräs; C G Regårdh
Journal:  Biopharm Drug Dispos       Date:  1990-10       Impact factor: 1.627

View more
  10 in total

1.  Evidence for dissolution rate-limited absorption of COL-3, a matrix metalloproteinase inhibitor, leading to the irregular absorption profile in rats after oral administration.

Authors:  Jing Li; Hung Huynh; Eli Chan
Journal:  Pharm Res       Date:  2002-11       Impact factor: 4.200

2.  A modified two-portion absorption model to describe double-peak absorption profiles of ranitidine.

Authors:  Ophelia Q P Yin; Brian Tomlinson; Albert H L Chow; Moses S S Chow
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 3.  Factors influencing the bioavailability of peroral formulations of drugs for dogs.

Authors:  S Sabnis
Journal:  Vet Res Commun       Date:  1999-11       Impact factor: 2.459

4.  Estimation of parameters for the elimination of an orally administered test substance with unknown absorption.

Authors:  Josef A Vogt; Christian Denzer
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-02-02       Impact factor: 2.745

5.  The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen.

Authors:  Werner Weitschies; Annika Bernsdorf; Thomas Giessmann; Michael Zschiesche; Christiane Modess; Vera Hartmann; Claudia Mrazek; Danilo Wegner; Stefan Nagel; Werner Siegmund
Journal:  Pharm Res       Date:  2005-05-17       Impact factor: 4.200

6.  Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo.

Authors:  U Wetterich; H Spahn-Langguth; E Mutschler; B Terhaag; W Rösch; P Langguth
Journal:  Pharm Res       Date:  1996-04       Impact factor: 4.200

7.  Understanding In Vivo Dissolution of Immediate Release (IR) Solid Oral Drug Products Containing Weak Acid BCS Class 2 (BCS Class 2a) Drugs.

Authors:  Min Li; Xinwen Zhang; Di Wu; Om Anand; Hansong Chen; Kimberly Raines; Lawrence Yu
Journal:  AAPS J       Date:  2021-10-26       Impact factor: 4.009

Review 8.  The Use of Physiologically Based Pharmacokinetic Analyses-in Biopharmaceutics Applications -Regulatory and Industry Perspectives.

Authors:  Om Anand; Xavier J H Pepin; Vidula Kolhatkar; Paul Seo
Journal:  Pharm Res       Date:  2022-05-18       Impact factor: 4.580

9.  Appearance of double peaks in plasma concentration-time profile after oral administration depends on gastric emptying profile and weight function.

Authors:  Yukiko Metsugi; Yoshihiro Miyaji; Ken-ichi Ogawara; Kazutaka Higaki; Toshikiro Kimura
Journal:  Pharm Res       Date:  2007-10-23       Impact factor: 4.200

10.  Pharmacokinetics Studies of 12 Alkaloids in Rat Plasma after Oral Administration of Zuojin and Fan-Zuojin Formulas.

Authors:  Ping Qian; You-Bo Zhang; Yan-Fang Yang; Wei Xu; Xiu-Wei Yang
Journal:  Molecules       Date:  2017-01-30       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.